Activation of cannabinoid CB(2) receptors attenuates thermal nociception in untreated animals while failing to produce centrally mediated effects such as @entity2332 and @entity8364 [Pain 93 (2001) 239]. The present study was conducted to test the hypothesis that activation of CB(2) in the periphery suppresses the development of @entity158 as well as @entity32 -evoked neuronal activity at the level of the CNS. The CB(2)-selective cannabinoid agonist @entity33748 (100, 330 micrograms/kg i.p.) suppressed the development of carrageenan-evoked thermal and @entity1931 and @entity1931 . The @entity33748 -induced suppression of carrageenan-evoked behavioral sensitization was blocked by the CB(2) antagonist @entity10029 but not by the CB(1) antagonist @entity351 . Intraplantar (ipl) administration of @entity33748 (33 micrograms/kg ipl) @entity1931 and @entity1931 following administration to the carrageenan-injected paw but was inactive following administration in the contralateral (noninflamed) paw, consistent with a local site of action. In immunocytochemical studies, @entity33748 suppressed spinal @entity5019 protein expression, a marker of neuronal activity, in the carrageenan model of @entity32 . @entity33748 suppressed carrageenan-evoked @entity5019 protein expression in the superficial and neck region of the dorsal horn but not in the nucleus proprius or the ventral horn. The suppression of carrageenan-evoked @entity5019 protein expression induced by @entity33748 was blocked by coadministration of @entity10029 in all spinal laminae. These data provide evidence that actions at cannabinoid CB(2) receptors are sufficient to suppress @entity32 -evoked neuronal activity at rostral levels of processing in the spinal dorsal horn, consistent with the ability of @entity33748 to normalize nociceptive thresholds and produce antinociception in @entity158 states.

Selective activation of cannabinoid CB(2) receptors suppresses spinal @entity5019 protein expression and @entity158 behavior in a rat model of XXXX .

@entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity10029 :: ('MESH:C110630', 'Chemical') :: ['SR144528'] @entity1931 :: ('MESH:D006930', 'Disease') :: ['mechanical hyperalgesia', 'allodynia', 'suppressed hyperalgesia'] @entity33748 :: ('MESH:C439263', 'Chemical') :: ['AM1241'] @entity5019 :: ('314322(Tax:10116)', 'Gene') :: ['Fos'] @entity8364 :: ('MESH:D002375', 'Disease') :: ['catalepsy'] @entity158 :: ('MESH:D010146', 'Disease') :: ['inflammatory pain'] @entity2332 :: ('MESH:D007035', 'Disease') :: ['hypothermia'] @entity351 :: ('MESH:C089032', 'Chemical') :: ['SR141716A']
@entity32 :: (MESH:D007249,Disease) :: ['inflammation']
